List view / Grid view
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
Investments are now being made to roll out this innovation across healthcare and broaden the scope of the research in this field.
A new research programme has been launched to produce all the human secreted proteins in mammalian cell factories. The programme aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
BenevolentAI is the first AI company to have a CMO on its staff.
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
It is difficult to estimate the global burden of cardiovascular disease in people with diabetes, due to lack of data and standardisation...
In this Imaging In-Depth Focus: Norman Peterson, from MedImmune/AstraZeneca, looks at the practical application of in vivo optical imaging in biotherapeutic biodistribution analyses. Plus, experts from MRC Technology discuss high-content imaging in drug discovery, and Molecular Devices feature in our Q&A...
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
4 August 2016 | By Niamh Marriott, Digital Content Producer
Chronos Therapeutics, a biotech company researching ageing diseases, brain and nervous system disorders, have announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development...
15 June 2016 | By Victoria White, Digital Content Producer
MRCT and AstraZeneca are seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases...
22 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has launched an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline...
